spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Nemera acquires Insight Product Development to strengthen its capabilities

Nemera


We are pleased to announce that Nemera has completed the acquisition of Insight Product Development, a 100% healthcare focused design and innovation consulting firm based in Chicago, IL (USA).

Insight delivers innovation in both medical and drug delivery devices services spanning the full development life cycle from early user research and human factors through to verification and design transfer. For decades, Insight Product Development has helped clients discover, innovate, and develop new product solutions through a user-centered design approach.

This set of capabilities will perfectly complement Nemera’s well established design center in La Verpillière (France). Located close to Nemera’s GMP manufacturing facility in Buffalo Grove, IL (USA), this strategic acquisition brings a strong development footprint in North America and significantly improves proximity to North America based customers.

The combination of both innovation organizations combines the strengths of Insight Product Development in front-end innovation, design research, human factors and design engineering with Nemera’s strong late-stage development, as well as clinical and commercial manufacturing capabilities. These newly enhanced capabilities enable Nemera to now offer complete end to end development services to all its customers globally and to collaborate with them earlier, supporting their complex drug delivery and medical device projects.

From today, Insight Product Development becomes an integral part of the newly branded Nemera’s “Insight Innovation Center”, with offices in La Verpillière, France and Chicago, IL.

Nemera’s Insight Innovation Center will leverage a large cross-disciplinary team of 150 passionate and dedicated innovation experts to develop tailored solutions across multiple device platforms, reflecting Nemera’s vision to put patients first through user centered research and design.

“Insight’s expertise of understanding patient needs and translating that into impactful product designs aligns perfectly with our purpose to ‘put patients first’.” – commented Marc Hämel, Nemera’s CEO – “This acquisition strengthens our engagement to take patients’ needs into account at every stage of product development cycle and to guarantee the best match with their needs”.

“Insight is very honored to be joining Nemera, a world class leader in the innovation and manufacture of so many impressive drug delivery systems.” - explained Craig Scherer, Insight Product Development’s Co-founder – “Bolstering Nemera’s front end offerings in user research and design, Insight is very pleased to help Nemera provide exceptional capabilities to their clients from innovation through industrialization.”

About NEMERA

Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera offers a comprehensive portfolio of products and services across ophthalmology, nasal, inhalation, dermal, transdermal and parenteral delivery. Nemera’s vision is to be the most patient-centric drug delivery device company. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients’ health, including off-the-shelf innovative systems, customized design development and GMP contract manufacturing.

About INSIGHT

Insight Product Development is a healthcare focused design and innovation consultancy. Since 1988, Insight has helped clients, from startups to Fortune 500 companies, uncover valuable opportunities, innovate the technologies and experiences that enable them, and drive their development through commercialization. Insight’s focus on understanding and supporting user needs throughout the patient journey has been the primary driver for developing processes and methods to better meet the needs of the client and the needs of patient. The research, human factors, design and engineering teams have extensive experience with both platform and novel devices never losing focus on the patient and improving healthcare outcomes.
phone +33 4 74 94 06 54
email information@nemera.net
web www.nemera.net
email 20 avenue de la Gare, 38290 – La Verpillière, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>


White Papers

Role of Comparators in Clinical Trial Supply

Clinical Services International

CSI analyses the role of comparators in different trial designs and offers expert advice on robust methodology for choosing the most appropriate comparators. Case studies provide real insight on how to choose comparators for rare diseases and oncology studies.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement